Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma. 2022

Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
Department of Otorhinolaryngology - Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan.

We investigated the survival impact and toxicity of maintenance metronomic chemotherapy in patients with metastatic/recurrent nasopharyngeal carcinoma (met/rec NPC). Ninety-eight patients with met/rec NPC were first salvaged by IV cisplatin-based chemotherapy and showed nonprogression disease; then maintenance metronomic chemotherapy for at least 12 months was recommended. We analyzed the treatment outcome between patients who received (n = 51) and did not receive (n = 47) maintenance chemotherapy. Baseline patient characteristics showed no significant differences between both arms. Median overall survival for patients with and without maintenance chemotherapy was 36.0 and 12.3 months, respectively (p < 0.0001). Similarly, median progression-free survival was 24.7 and 7.3 months, respectively (p < 0.0001). Furthermore, toxicities during maintenance oral chemotherapy period were usually mild. Transient grade 3 leucopenia (9.8%), anemia (3.9%), thrombocytopenia (7.8%), and no grade 4 toxicity were observed. After IV salvage chemotherapy, maintenance oral metronomic chemotherapy significantly improved overall and progression-free survivals while demonstrating low toxicity in patients with met/rec NPC.

UI MeSH Term Description Entries
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077274 Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes. Carcinoma, Nasopharyngeal,Carcinomas, Nasopharyngeal,Nasopharyngeal Carcinomas
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D018572 Disease-Free Survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. Survival, Disease-Free,Disease Free Survival,Survival, Disease Free

Related Publications

Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
August 1989, Journal of chemotherapy (Florence, Italy),
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
July 2021, Lancet (London, England),
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
December 2002, Cancer,
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
April 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
May 2024, NPJ precision oncology,
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
August 2022, JAMA oncology,
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
August 2022, JAMA oncology,
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
January 2020, Therapeutic advances in medical oncology,
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
October 2022, Cancer communications (London, England),
Chih-Wen Twu, and Po-Ju Lin, and Hsiao-Hui Tsou, and Yi-Chun Liu, and Rong-San Jiang, and Kai-Li Liang, and Tian-Yun Lin, and Wen-Yi Wang, and Jin-Ching Lin
January 2022, Oncology research and treatment,
Copied contents to your clipboard!